Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 805 results for "juno"

Juno Therapeutics IPO: Stock soars 60 percent on debut
Seattle TechFlash

Juno Therapeutics IPO Caps Big Year In Biotech Deals

Juno Therapeutics (NASDAQ: JUNO ) set a record as the most highly valued biotech IPO this year, with the stock jumping 62% as trading began Friday. The initial public offering raised $265 million, with the company selling 11 million shares at 24. Investor's Business Daily, 22 hours ago

379 images for juno

CNBC, 21 hours ago
Daily Sports Car, 1 day ago
Peterborough Examiner, 10 hours ago
Chicago Daily Herald, 13 hours ago
One News Page United Kingdom, 2 days ago
Bidness Etc, 1 day ago
Technology Tell, 5 days ago
Meridian Booster, 4 days ago
Xconomy, 15 hours ago
Your Tango, 1 day ago

Juno Therapeutics Surges in Debut

Juno Therapeutics Inc. shares surged 63% in their market debut Friday, after a flurry of demand for the year's last expected new offering led the biotech firm to price above its already-boosted range. Juno, which develops cancer treatments that use ...
 Austin American Statesman23 hours ago Juno Therapeutics' stock surges in market debut  Yahoo! UK and Ireland23 hours ago Shares of cancer treatment maker Juno Therapeutics surge 60 per cent in stock market debut  Canadian Business Magazine23 hours ago JUNO THER : peutics Shares Surge in Market Debut  4 Traders1 day ago

Juno Therapeutics IPO Hot As Cancer Curers In Demand

Juno Therapeutics soared 46% in Friday's trading debut, the latest sign of investor demand for a new class of cancer-curing firms and for biotechs overall. Juno (NASDAQ: JUNO ) raised $265 million late Thursday in its IPO with an initial market ...
 Investor's Business Daily16 hours ago Juno Therapeutics soars in Nasdaq debut  Austin American Statesman23 hours ago Cancer drug developer Juno Therapeutics rises 64.5 pct in debut  CNBC1 day ago Juno Therapeutics Ups IPO Price In Hot Biotech Field  Investor's Business Daily3 days ago

Is Juno Worth Buying After Its Explosive IPO?

One of the most exciting companies in biotech just had one of the year's most exciting initial public offerings. Shares of Seattle-based Juno Therapeutics increased 60% from their listing price to $38 in late morning trading in the biggest ...
 Forbes.com16 hours ago Juno Shares Exploded Post-IPO. Should You Consider Buying Them?  Austin American Statesman22 hours ago I.P.O. of Juno Therapeutics, Developer of a Cancer Treatment, Excites Investors  Global Advisors14 hours ago

Juno Joins Bespoke Cancer Treatment Frenzy as Questions Linger

(Bloomberg) -- It's a cancer therapy straight out of Greek mythology, bespoke medicine with astonishing results in the smallest and sickest of patients. The treatment, called a chimeric antigen receptor, or CAR for short, has captured the attention ...
 Washington Post22 hours ago Juno Joins Bespoke Cancer Therapy Frenzy as Questions Linger  Washington Post16 hours ago

Photo Release -- Nasdaq Welcomes Juno Therapeutics (Nasdaq: JUNO) to The Nasdaq Stock Market

NEW YORK, Dec. 19, 2014 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) announced that trading of Juno Therapeutics (Nasdaq:JUNO), a biopharmaceutical company, commenced on The Nasdaq Stock Market on December 19, 2014. A photo accompanying this release is ...
 Wall Street Select23 hours ago Juno, the Last IPO of 2014, Enters the Market With a Bang  24/7 Wall St1 day ago Juno Therapeutics (Nasdaq: JUNO) to Ring The Nasdaq Stock Market Opening Bell in Celebration of IPO  Financial Content1 day ago Photo Release — Nasdaq Welcomes Juno Therapeutics (Nasdaq: JUNO) to The Nasdaq Stock Market  Consumer Electronics Net22 hours ago
Seattle TechFlash

Next year may be big for IPOs

The IPO business: This year was huge for initial public offerings, and 2015 may be even better. With Juno Therapeutics' IPO on Friday, we will end one of the biggest years ever for IPOs, the biggest since 2000, which was the record year. ...
 CNBC1 day ago Blowout Year for IPOs to End With Juno's Big Biotech Offering  Dow Jones Financial Information Services1 day ago The year of the biotech IPO: Many of Seattle's newest public companies are lab-driven  Seattle TechFlash2 days ago A big year for IPOs-next year may be even bigger  Yahoo! Xtra Business1 day ago

IPO Preview: Juno Therapeutics

Summary Building a fully-integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body's immune system to treat cancer. Phase II trial 'before the end of 2015'. 3.4 times book, which is 'in range'. P/E of -18 ...
 Seeking Alpha1 day ago IPO Report: Juno Therapeutics (JUNO)  Equities.com1 day ago

Bellicum Leaps On Biotech IPO, Setting Stage For Juno

Capping what has been a big year for biotech IPOs, Bellicum Pharmaceuticals (NASDAQ: BLCM ) bolted on its public debut Thursday, with Juno Therapeutics coming next. Bellicum raised $140 million by offering 7.35 million shares at 19, above its ...
 Investor's Business Daily1 day ago

Bellicum off to a strong start

News Editor IPO Bellicum Pharmaceuticals (NASDAQ:BLCM) debuts strongly. Shares are up 41% on turnover of 6.3M. Juno Therapeutics (Pending:JUNO) is on deck for tomorrow. Previously: Bellicum Pharma on deck for IPO (Dec.
 Seeking Alpha1 day ago Bellicum pulls off a $140M IPO as CAR-T has its day on Wall Street  FierceBiotech2 days ago Houston's Bellicum Pharma Rides T-Cell Therapy Wave to $140M IPO  Xconomy2 days ago IPO Preview: Bellicum Pharmaceuticals  Seeking Alpha2 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less